Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection

被引:4
作者
Kumar, Neil R. [1 ]
Karanam, Veena C. [2 ]
Kumar, Shari [3 ]
Kumar, Sunil D. [4 ,5 ]
机构
[1] Univ Miami, Jackson Mem Hosp, Internal Med, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Miami, FL USA
[3] Columbia Univ, Coll Dent Med, New York, NY USA
[4] Broward Hlth Med Ctr, Pulm Crit Care, Ft Lauderdale, FL 33316 USA
[5] Broward Hlth Med Ctr, 1600 S Andrews Ave, Ft Lauderdale, FL 33316 USA
关键词
convalescent plasma; COVID-19; severe; late stage; life threatening;
D O I
10.14423/SMJ.0000000000001546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesCurrent evidence favors plasma to be effective against coronavirus disease 2019 (COVID-19) in critically ill patients in the early stages of infection. We investigated the safety and efficacy of convalescent plasma in specifically late-stage (designated as after 2 weeks of hospital admission) severe COVID-19 infection. We also conducted a literature review on the late-stage use of plasma in COVID-19.MethodsThis case series examined eight COVID-19 patients admitted to the intensive care unit (ICU) who met criteria for severe or life-threatening complications. Each patient received one dose (200 mL) of plasma. Clinical information was gathered in intervals of 1 day pretransfusion and 1 hour, 3 days, and 7 days posttransfusion. The primary outcome was effectiveness of plasma transfusion, measured by clinical improvement, laboratory parameters, and all-cause mortality.ResultsEight ICU patients received plasma late in the course of COVID-19 infection, on average at 16.13 days postadmission. On the day before transfusion, the averaged initial Sequential Organ Failure Assessment (SOFA) score, PaO2:FiO(2) ratio, Glasgow Coma Scale (GCS), and lymphocyte count were 6.5, 228.03, 8.63, and 1.19, respectively. Three days after plasma treatment, the group averages for the SOFA score (4.86), PaO2:FiO(2) ratio (302.73), GCS (9.29), and lymphocyte count (1.75) improved. Although the mean GCS improved to 10.14 by posttransfusion day 7, the other means marginally worsened with an SOFA score of 5.43, a PaO2:FiO(2) ratio of 280.44, and a lymphocyte count of 1.71. Clinical improvement was noted in six patients who were discharged from the ICU.ConclusionsThis case series provides evidence that convalescent plasma may be safe and effective in late-stage, severe COVID-19 infection. Results showed clinical improvement posttransfusion as well as decreased all-cause mortality in comparison to pretransfusion predicted mortality. Randomized controlled trials are needed to conclusively determine benefits, dosage, and timing of treatment.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 50 条
[21]   The efficacy of convalescent plasma therapy in severe COVID-19 patients: a systematic review [J].
Muddasani, Swathi ;
Kotlarsic, Zar ;
Agadi, Kuchalambal ;
Jeu, Michelle ;
Chavarria, Amanda ;
Edaki, Omoyeme ;
Sanchez-Gonzalez, Marcos .
EUROPEAN RESPIRATORY JOURNAL, 2021, 58
[22]   Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study [J].
Ghadami, Ladan ;
Hasibi, Mehrdad ;
Asadollahi-Amin, Ali ;
Asanjarani, Behzad ;
Farahmand, Mohammad ;
Abdollahi, Hamed .
MICROBIAL PATHOGENESIS, 2022, 165
[23]   Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19 [J].
Raturi, Manish ;
Kala, Mansi ;
Das, Kunal ;
Kusum, Anuradha .
JOURNAL OF LABORATORY PHYSICIANS, 2021, 13 (01) :91-94
[24]   Convalescent plasma therapy in the treatment of COVID-19: Practical considerations [J].
Islam, Amin ;
Rafiq, Shafquat ;
Karim, Sabina ;
Laher, Ismail ;
Rashid, Harunor .
INTERNATIONAL JOURNAL OF SURGERY, 2020, 79 :204-205
[25]   COVID-19 convalescent plasma composition and immunological effects in severe patients [J].
Acosta-Ampudia, Yeny ;
Monsalve, Diana M. ;
Rojas, Manuel ;
Rodriguez, Yhojan ;
Esteban Gallo, Juan ;
Carlos Salazar-Uribe, Juan ;
Jose Santander, Maria ;
Cala, Monica P. ;
Zapata, Wildeman ;
Isabel Zapata, Maria ;
Manrique, Ruben ;
Mauricio Pardo-Oviedo, Juan ;
Camacho, Bernardo ;
Ramirez-Santana, Carolina ;
Anaya, Juan-Manuel .
JOURNAL OF AUTOIMMUNITY, 2021, 118
[26]   Convalescent plasma for COVID-19 considerations [J].
Pawitan, Jeanne Adiwinata .
TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (01)
[27]   Use of convalescent plasma in COVID-19 [J].
David Macedo-Reynada, J. ;
Ventura-Enriquez, Yanet .
GACETA MEDICA DE MEXICO, 2021, 157 :68-78
[28]   Effect of convalescent plasma in the treatment of severe acute respiratory distress syndrome caused by COVID-19 infection [J].
Lukic-Sarkanovic, Mirka ;
Vico-Katanic, Nina ;
Jerkovic, Milica ;
Joksic-Mazinjanin, Radojka ;
Terzic, Neda ;
Zdravkovic, Ranko .
SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2024, 152 (5-6) :238-243
[29]   Efficacy and safety of convalescent plasma administration in patients with COVID-19 infection [J].
Escobedo-Sanchez, Priscila Edith ;
de la Cruz-Hernandez, Ibis ;
Ramos-Garcia, Meztli ;
Sanchez-Yedra, Ivan ;
Garcia-Vazquez, Carlos ;
Guzman-Priego, Crystell Guadalupe ;
Garcia-Vidrios, Maria Victoria ;
Olvera-Hernandez, Viridiana ;
Mendoza-Garcia, Yolanda ;
Ble-Castillo, Jorge Luis .
MEDICINA CLINICA, 2023, 161 (08) :323-329
[30]   International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection [J].
Murphy, Michael ;
Estcourt, Lise ;
Grant-Casey, John ;
Dzik, Sunny .
TRANSFUSION MEDICINE REVIEWS, 2020, 34 (03) :151-157